PerkinElmer

Maternal pre-eclampsia, chromosomal abnormalities, and newborn metabolic disorders are few of the major causes of newborn mortality in today’s world. To reduce these mortality rates, clinical intervention is needed before birth. PerkinElmer’s solutions are specially designed to provide predictive support in identifying the pregnancies where intervention can benefit the outcome.

One of the global leaders in prenatal and newborn screening
PerkinElmer, having over 30 years of rich experience, is the global market leader in prenatal screening for Down Syndrome (Trisomy 21), Edward syndrome (Trisomy 18), Patau syndrome (Trisomy 13), ONTDs, Pre-eclampsia, and newborn screening solution ranging from basic to expanded panel of assays.

Detecting earlier to enable healthier outcomes for mothers and babies
Using our instruments and assays, over 10 million prenatal risk assessments and over 35 million babies are being screened annually. Since 1985, almost 600 million babies have been screened. Every day, more than 70 babies around the world get a healthier start to life – thanks to the early detection of serious disorders.

PerkinElmer offers complete range of high-quality and validated products including screening assays, instruments, and software which helps prevent disabilities and fatalities among mothers and children. Today, PerkinElmer works closely with hospitals, laboratories, fetal medicine specialists, geneticists, and government bodies for regional and national programs to make screening more accessible.

The company’s first and second trimester prenatal screening and newborn screening uses CE-marked instruments, reagents and assays coupled with state-of-the-art Delfia technology. Its high performance assures high degree of sensitivity and specificity that has been widely acknowledged and has been used in numerous key international studies.

Delfia’s time-resolved fluorescence technology is the preferred choice for prenatal and newborn screening programs globally.

• Prenatal screening
  Evidence and guideline-based screening programs for aneuploidies and pre-eclampsia combine markers, accredited technology, and assays for high-detection rates with low numbers of false
  positives. PerkinElmer is the pioneer in dried blood-spot (DBS) technology in prenatal screening. Range of instruments include:

  AutoDELFIA: Fully automated batch analyzer for large-sized labs

• DELFIA XPRESS: Random access analyzer for mid-sized labs
• VICTOR 2D: Semi-automated batch instrument for small-sized labs

PerkinElmer is one of the companies that offers four CE-marked assays – PAPP-A, free hCGß, PlGF, and AFP (1T QUAD) – for first-trimester screening of Down Syndrome. PlGF marker can be used for aneuploidy in addition to pre-eclampsia screening with other ultrasound markers. Second-trimester assays include AFP, free hCGß/hCG, uE3, and Inhibin-A. Company’s instruments and assays are Fetal Medicine Foundation (FMF) approved for first trimester, clinically validated, and support all modern prenatal screening strategies and contingent testing with NIPT. Together with LifeCycle software, PerkinElmer’s high-quality assays help you to achieve high performance in screening program.

Newborn screening

• Range of solutions
• PerkinElmer 226 cards: DBS sample collection
• Panthera-Puncher 9: Fully automated puncher
• GSP and AutoDelfia: Fully automated screening system
• VICTOR 2D: Ideal system for low-volume laboratories
• QSight 210 MD: For expanded newborn screening (>57 analytes using NeoBase 2 and Neo LSD – 6 LSD disorders)
• Migele: For screening hemoglobin disorders
• Specimen Gate Essentials: Informatics solution

PerkinElmer works closely with FMF and key opinion leaders globally to provide best-in-class solutions to adapt to all laboratory needs, from low volume manual instruments to automated high-throughput platforms. In addition, the company offers statistical services and software to support in building and managing the screening programs. PerkinElmer’s global presence and holistic understanding of prenatal and newborn screening enables it to ensure a better life every day through use of innovation and know-how effectively.